Previous 10 | Next 10 |
2023-05-15 10:45:51 ET Benitec press release ( NASDAQ: BNTC ): Q3 GAAP EPS of -$0.16. Revenue of $0.54M (+12.5% Y/Y). For further details see: Benitec GAAP EPS of -$0.16, revenue of $0.54M
HAYWARD, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ...
HAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ...
HAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ...
Retail traders have turned to Robinhood as a popular platform for trading stocks. With its user-friendly interface and commission-free trading, Robinhood has made stock trading accessible to a wider audience. Traders are particularly attracted to low-priced stocks, commonly known as penny sto...
Benitec press release ( NASDAQ: BNTC ): Q2 GAAP EPS of -$0.20 misses by $0.09 . As of December 31, 2022, the Company had $10.5 million in cash and cash equivalents. Shares +1.70% PM For further details see: Benitec GAAP EPS of -$0.20 misses by $0.09
HAYWARD, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference...
HAYWARD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interfer...
Benitec press release ( NASDAQ: BNTC ): Q3 GAAP EPS of -$0.47. Total Expenses for the quarter ended September 30, 2022, were $4.6 million compared to $4.8 million for the quarter ended September 30, 2021. For further details see: Benitec GAAP EPS of -$0.47
HAYWARD, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA in...
News, Short Squeeze, Breakout and More Instantly...
Benitec Biopharma Limited Company Name:
BNTC Stock Symbol:
NASDAQ Market:
Benitec Biopharma Limited Website:
2024-07-16 20:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-The post-dose average values for Total Pharyngeal Residue (i.e., the amount of solid food or liquid material remaining in the pharynx after the first swallow) remained meaningfully reduced at the 180-day post-dose assessment following the administration of the low dose of gene therapy BB-301 as ...
HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace ...